Lynx1 Capital Management
Latest statistics and disclosures from Lynx1 Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are Alpine Immune Sciences, MRUS, STOK, TCRX, CABA, and represent 73.20% of Lynx1 Capital Management's stock portfolio.
- Added to shares of these 9 stocks: MRUS (+$17M), GHRS (+$16M), STOK (+$10M), SLN (+$6.3M), PASG (+$6.0M), CCCC, IBIO, CNTA, NKTR.
- Started 2 new stock positions in CNTA, IBIO.
- Reduced shares in these 7 stocks: Alpine Immune Sciences (-$62M), AUTL, Theseus Pharmaceuticals, CABA, Pieris Pharmaceuticals, Kinnate Biopharma, BNOX.
- Sold out of its position in Theseus Pharmaceuticals.
- Lynx1 Capital Management was a net seller of stock by $-6.7M.
- Lynx1 Capital Management has $388M in assets under management (AUM), dropping by 52.66%.
- Central Index Key (CIK): 0001910456
Tip: Access up to 7 years of quarterly data
Positions held by Lynx1 Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv![Download consolidated filings csv](/static/img/csv.png)
![Download consolidated filings xlsx](/static/img/microsoft-excel.png)
Portfolio Holdings for Lynx1 Capital Management
Lynx1 Capital Management holds 16 positions in its portfolio as reported in the March 2024 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
---|---|---|---|---|---|---|
Alpine Immune Sciences | 23.0 | $89M | -40% | 2.3M | 39.64 |
|
Merus N V (MRUS) | 17.5 | $68M | +32% | 1.5M | 45.03 |
|
Stoke Therapeutics (STOK) | 12.9 | $50M | +25% | 3.7M | 13.50 |
|
Tscan Therapeutics (TCRX) | 10.7 | $42M | 5.2M | 7.94 |
|
|
Cabaletta Bio (CABA) | 9.2 | $36M | 2.1M | 17.06 |
|
|
Gh Research Ordinary Shares (GHRS) | 9.1 | $35M | +80% | 3.3M | 10.66 |
|
C4 Therapeutics Com Stk (CCCC) | 7.6 | $30M | +15% | 3.6M | 8.17 |
|
Silence Therapeutics Ads (SLN) | 2.9 | $11M | +123% | 527k | 21.60 |
|
Autolus Therapeutics Spon Ads (AUTL) | 2.3 | $8.9M | -25% | 1.4M | 6.38 |
|
Passage Bio (PASG) | 1.7 | $6.5M | +1178% | 4.8M | 1.35 |
|
Kinnate Biopharma | 1.4 | $5.3M | 2.0M | 2.66 |
|
|
Ibio Con New (IBIO) | 0.6 | $2.4M | NEW | 600k | 4.06 |
|
Nektar Therapeutics (NKTR) | 0.5 | $1.9M | +7% | 2.1M | 0.93 |
|
Pieris Pharmaceuticals | 0.4 | $1.6M | -10% | 8.8M | 0.18 |
|
Bionomics Ads (BNOX) | 0.2 | $839k | 815k | 1.03 |
|
|
Centessa Pharmaceuticals Sponsored Ads (CNTA) | 0.1 | $197k | NEW | 17k | 11.30 |
|
Past Filings by Lynx1 Capital Management
SEC 13F filings are viewable for Lynx1 Capital Management going back to 2021
- Lynx1 Capital Management 2024 Q1 amended filed May 30, 2024
- Lynx1 Capital Management 2024 Q1 filed May 15, 2024
- Lynx1 Capital Management 2023 Q4 filed Feb. 14, 2024
- Lynx1 Capital Management 2023 Q3 filed Nov. 14, 2023
- Lynx1 Capital Management 2023 Q2 filed Aug. 14, 2023
- Lynx1 Capital Management 2023 Q1 filed May 15, 2023
- Lynx1 Capital Management 2022 Q4 filed Feb. 14, 2023
- Lynx1 Capital Management 2022 Q3 filed Nov. 14, 2022
- Lynx1 Capital Management 2022 Q2 filed Aug. 15, 2022
- Lynx1 Capital Management 2022 Q1 filed May 16, 2022
- Lynx1 Capital Management 2021 Q4 filed Feb. 14, 2022